Treatment Updates for Relapsed/Refractory AML

In round one of their discussion on Acute Myeloid Leukemia, Catherine Lai, MD, and Alice Mims, MD, discuss treatment updates from EHA2024 for recurrent/progressive AML patients.
November 21, 2024 • 4 mins 32 secs
Up Next
Treatment Updates for Relapsed/Refractory AML
▶ 4 mins
image
2024 Update on Menin Inhibitors in AML
▶ 3 mins
image
I-Data study: Newly Diagnosed IDH Mutated AML Patients
▶ 3 mins
image
Comparing IDH1 Inhibitors: Ivosidenib vs. Olutasidenib in Relapsed/Refractory Settings
▶ 3 mins
image
Exploring IRAK4 and FLT3 Inhibitors in AML: The Take AIM Study
▶ 2 mins
image
New Targets in AML: CLIC-2, Polo-like Kinase Inhibitors, and TP53 Mutation Strategies
▶ 3 mins
image
Advances in AML and Bone Marrow Transplants
▶ 4 mins
image
Enhancing Post-Transplant Co-Management
▶ 2 mins
image
Testing Options in AML
▶ 4 mins
image